Kuano

Kuano is a private, pre-revenue biotechnology platform company applying a unique synergy of quantum simulation and AI to drug design. Its proprietary platform integrates automated quantum mechanics (QM), molecular dynamics (MD), and AI methods like reaction-informed graph neural networks (GNNs) to rapidly explore chemical space for difficult targets such as phosphatases and metalloproteases. Led by a team of quantum physicists, computational chemists, and drug discovery veterans, the company is backed by seed investors and grants and operates as a service/partnering model to advance therapeutic programs for clients. Kuano aims to redefine drug discovery by merging advanced computation with deep scientific insight.

Proprietary integrated platform combining quantum mechanics (QM), molecular dynamics (MD), QMMM simulations, and AI/ML (e.g., reaction-informed GNNs, active learning) for accelerated drug discovery and design, specifically for challenging targets.

Kuano competes in the computational drug discovery space against established software providers (e.g., Schrödinger), pure-play AI-biotech companies (e.g., Exscientia, Recursion), and internal pharma efforts. Its differentiation lies in the deep integration of quantum simulation methods with AI, a focus few competitors emphasize, targeting the most challenging biological targets.